InvestSMART

Cambium Bio Limited (ASX: CMB) - Announcements

Current share price for CMB : $0.545 0.025 (4.81%)+

ASX company news and announcements for Cambium Bio Limited (CMB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cambium Bio Limited (CMB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cambium Bio Limited (CMB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cambium Bio Limited (CMB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$16 Cambium Bio Signs US$2.0M plus Licensing Deal 2 Sep 2025 1:07PM $0.465 $0.545 risen by 17.20%
$16 FY25 Appendix 4G and Corporate Governance Statement 29 Aug 2025 4:00PM $0.470 $0.545 risen by 15.96%
$16 FY25 Appendix 4E and Annual Report 29 Aug 2025 3:56PM $0.470 $0.545 risen by 15.96%
$16 FY25 Appendix 4E and Annual Report 29 Aug 2025 3:56PM $0.470 $0.545 risen by 15.96%
$16 Cleansing notice 29 Aug 2025 9:23AM $0.440 $0.545 risen by 23.86%
$16 Application for quotation of securities - CMB 29 Aug 2025 9:21AM $0.440 $0.545 risen by 23.86%
$16 Update - Proposed issue of securities - CMB 27 Aug 2025 11:35AM $0.360 $0.545 risen by 51.39%
$16 Placement Participant Update 27 Aug 2025 11:27AM $0.360 $0.545 risen by 51.39%
$16 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2025 11:39AM $0.460 $0.545 risen by 18.48%
$16 Proposed issue of securities - CMB 30 Jul 2025 11:14AM $0.290 $0.545 risen by 87.93%
$16 Cambium Bio Raises A$2.12 million 30 Jul 2025 11:14AM $0.290 $0.545 risen by 87.93%
$16 Cambium Bio Clears FDA Regulatory Hurdles 11 Jul 2025 9:10AM $0.215 $0.545 risen by 153.49%
$16 Cambium Bio Receives Ethics Approvals 30 Jun 2025 9:23AM $0.210 $0.545 risen by 159.52%
$16 Change of Address 23 May 2025 3:56PM $0.190 $0.545 risen by 186.84%
$16 Initial Director's Interest Notice - Denese Marks 22 May 2025 4:36PM $0.190 $0.545 risen by 186.84%
$16 Final Director's Interest Notice - Barry Sechos 22 May 2025 4:35PM $0.190 $0.545 risen by 186.84%
$16 Board and Company Secretary Changes 21 May 2025 12:32PM $0.190 $0.545 risen by 186.84%
$16 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2025 9:55AM $0.290 $0.545 risen by 87.93%
$16 Change of registry address 14 Apr 2025 5:07PM $0.280 $0.545 risen by 94.64%
$16 Notice of ceasing to be a substantial holder 11 Apr 2025 3:05PM $0.280 $0.545 risen by 94.64%
$16 Cambium Bio - Release of Shares from Escrow 21 Mar 2025 6:38PM $0.350 $0.545 risen by 55.71%
$16 Notice of change of interests of substantial holder-CMB 18 Mar 2025 6:07PM $0.350 $0.545 risen by 55.71%
$16 FDA Approves Cambium Bio's Potency Assay Strategy for Elate 18 Mar 2025 10:58AM $0.350 $0.545 risen by 55.71%
$16 Change of Directors Interest Notice 12 Mar 2025 6:11PM $0.350 $0.545 risen by 55.71%
$16 Notification regarding unquoted securities - CMB 12 Mar 2025 4:37PM $0.350 $0.545 risen by 55.71%

51 - 75 of 142 results

Page 3 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.